Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sophie Gillette is active.

Publication


Featured researches published by Sophie Gillette.


Journal of the American Geriatrics Society | 2004

Improvement of Weight and Fat‐Free Mass with Oral Nutritional Supplementation in Patients with Alzheimer's Disease at Risk of Malnutrition: A Prospective Randomized Study

Sylvie Lauque; Franck Arnaud-Battandier; Sophie Gillette; Jean-Marie Plaze; Sandrine Andrieu; Christelle Cantet; Bruno Vellas

Objectives: To study the effects of oral nutritional supplements (OS) on body weight, body composition, nutritional status, and cognition in elderly patients with Alzheimers disease (AD).


Medical Clinics of North America | 2011

Treatment Strategies for Sarcopenia and Frailty

Yves Rolland; Charlotte Dupuy; Gabor Abellan van Kan; Sophie Gillette; Bruno Vellas

Sarcopenia is the key feature of frailty in older people and a major determinant of adverse health outcomes such as functional limitations and disability. Resistance training and adequate protein and energy intake are the key strategies for the management of sarcopenia. Management of weight loss and resistance training are the most relevant protective countermeasures to slow down the decline of muscle mass and muscle strength. The quality of amino acids in the diet is an important factor for stimulating protein synthesis. Vitamin D deficiency should be treated, and new pharmacologic approaches for sarcopenia are currently assessed.


Health Economics Review | 2012

Methodological considerations in cost of illness studies on Alzheimer disease

Nagede Costa; Hélène Derumeaux; Thomas Rapp; Valérie Garnault; Laura Ferlicoq; Sophie Gillette; Sandrine Andrieu; Bruno Vellas; Michel Lamure; Alain Grand; Laurent Molinier

Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct, indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify which dimension had to be improved from a methodological perspective. First, we described the key points of cost study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of the different methods used. The methodological choices of the studies were analysed using an analytical grid which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the studies, annual total costs per patient vary from


Journal of Nutrition Health & Aging | 2013

Dietary vitamin D intake and muscle mass in older women. Results from a cross-sectional analysis of the EPIDOS study

Charlotte Dupuy; Valérie Lauwers-Cancès; G. Abellan Van Kan; Sophie Gillette; Anne-Marie Schott; O. Beauchet; C. Annweiler; Bruno Vellas; Yves Rolland

2,935 to


International Journal of Geriatric Psychiatry | 2013

A follow-up intervention in severely demented patients after discharge from a special Alzheimer acute care unit: impact on early emergency room re-hospitalization rate

Hélène Villars; Charlotte Dupuy; Pauline Soler; Virginie Gardette; Maria Soto; Sophie Gillette; Fati Nourhashemi; BrunoVellas

52, 954. The methods, data sources, and estimated cost categories in each study varied widely. The review showed that cost studies adopted different approaches to estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility, closer agreement among researchers on the methodological principles of cost studies would be desirable.


Journals of Gerontology Series A-biological Sciences and Medical Sciences | 2003

Association of Alzheimer's Disease Onset With Ginkgo Biloba and Other Symptomatic Cognitive Treatments in a Population of Women Aged 75 Years and Older From the EPIDOS Study

Sandrine Andrieu; Sophie Gillette; Karine Amouyal; Fati Nourhashemi; Emma Reynish; Pierre Jean Ousset; Jean Louis Albarede; Bruno Vellas; Hélène Grandjean

ObjectivesVitamin D intake may prevent physical performance decline through prevention of muscle mass loss. Our objective was to determine whether low dietary intakes were associated with low muscle mass (MM).Design and participantsCross-sectional analysis of 1989 community-dwelling women (mean age 80.5±3.8years) from the EPIDémiologie de l’OStéoporose (EPIDOS) study were assessed at baseline.MeasurementsLow intakes of vitamin D (<70µg/week) were estimated from the weekly dietary vitamin D intakes (self-administered food frequency questionnaire). Low MM was defined according to the appendicular skeletal muscle mass index assessed using Dual Energy X-ray Absorptiometry, divided by square height of less than 5.45 kg/m2. Usual gait speed defined physical performance. Age, sun exposure, co-morbidities, education level, living arrangements, recreational physical activity, dietary protein and calcium intakes, bone mineral density, handgrip strength, and body mass index were considered as potential confounders. Multivariate logistic regression analyses assessed the association between low vitamin D intakes and low MM.ResultsTwo-hundred and nine (10.5%) women with low MM were compared to 1,780 women with normal MM. In final model, obesity/overweight (Adjusted Odds Ratios, aOR=0.09; 95%CI [0.05–0.17]), malnutrition (aOR=3.90; 95%CI [2.74–5.54]) and low handgrip strength (aOR=2.33; 95%CI [1.44–3.77]; p<0.001) were statistically associated with a low MM status.ConclusionNo association with low MM has been reported regarding low dietary intakes of vitamin D.


American Journal of Cardiovascular Drugs | 2013

Factors Associated with Undertreatment of Atrial Fibrillation in Geriatric Outpatients with Alzheimer Disease

Neda Tavassoli; Amélie Perrin; Emilie Bérard; Sophie Gillette; Bruno Vellas; Yves Rolland

Emergency room (ER) re‐hospitalizations are prevalent in severe Alzheimers disease affected older patients.


La Revue du praticien | 2005

[Managing Alzheimer's disease: global care and support program].

Fati Nourhashemi; Sophie Gillette; Sandrine Andrieu


Alzheimers & Dementia | 2011

Multidomain Alzheimer's disease preventive trial: Florbetapir ancillary study.

Julien Delrieu; Pierre Payoux; Anne Hitzel; Sophie Peiffer; Gabor Abellan van Kan; Sophie Gillette; Andrieu Sandrine; Bruno Vellas


Alzheimers & Dementia | 2009

The Multidomain Alzheimer Preventive Trial (MAPT): A new approach for the prevention of Alzheimer's disease

Sophie Gillette

Collaboration


Dive into the Sophie Gillette's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Anne Hitzel

University of Toulouse

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge